 Development of an expected () profile.

 Development of ()plans and post-marketing safety studies.

 () about medicines safety

 Supplementing the ()available from premarketing studies – better quantitation of the incidence of known adverse and beneficial effects, e.g., in patients not studied prior to marketing (e.g., the elderly, pregnant women); as modified by other medicines and other illnesses; relative to other medicines used for the same indication